ADMA - Company ID 0001368514
The table below shows ADMA BIOLOGICS, INC.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | $58.25M | -$19.68M | -$2.22M | -$14.72M | -$26.01M | -$33.23M |
| Capital expenditure | $2.54M | $4.70M | $2.35M | $1.95M | $2.84M | $2.57M |
| Investing cash flow | $2.40M | -$4.72M | -$2.36M | -$1.95M | -$2.84M | -$2.57M |
| Dividends paid | - | - | - |
ADMA BIOLOGICS, INC. reported operating cash flow of $50.40M for fiscal year 2025. That is down 57.5% from $118.67M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from -$18.27M (FY 2016) to $50.40M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Stock buybacks | $130.19M | $0.00 | - | - | - | - |
| Financing cash flow | -$10.13M | -$7.13M | -$1.45M | -$650.00K | $47.27M | $41.84M |